Cosmo Pharmaceuticals GAAP EPS of -€0.23, revenue of €104.17M; introduces FY26 outlook

AI Briefing

• – Cosmo Pharmaceuticals reports FY26 GAAP EPS of -€0.23 and €104.17M revenue, down -61.0% Y/Y.
• – Recurring revenues of €88.1M increased by 15% year-over-year.
• – Cosmo Pharmaceuticals introduces FY26 outlook.